Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Guangzhou Baiyunshan Pharmaceutical Holdings Co's quarterly raw materials
increased
from Sep. 2025 (HK$0 Mil) to Dec. 2025 (HK$1,006 Mil) but then
declined
from Dec. 2025 (HK$1,006 Mil) to Mar. 2026 (HK$0 Mil).
Guangzhou Baiyunshan Pharmaceutical Holdings Co's annual raw materials
declined
from Dec. 2023 (HK$1,232 Mil) to Dec. 2024 (HK$1,175 Mil) and
declined
from Dec. 2024 (HK$1,175 Mil) to Dec. 2025 (HK$1,006 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Inventories, Raw Materials & Components Chart
Guangzhou Baiyunshan Pharmaceutical Holdings Co Annual Data
What does a Inventories, Raw Materials & Components of HK$0 Mil mean?
Guangzhou Baiyunshan Pharmaceutical Holdings Co (HKSE:00874) has a Inventories, Raw Materials & Components of HK$0 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co's Inventories, Raw Materials & Components too high?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Inventories, Raw Materials & Components is HK$0 Mil. Overall, Guangzhou Baiyunshan Pharmaceutical Holdings Co has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Baiyunshan Pharmaceutical Holdings Co's Inventories, Raw Materials & Components compare to MCK and COR?
Guangzhou Baiyunshan Pharmaceutical Holdings Co's Inventories, Raw Materials & Components of HK$0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Medical Distribution company?
A good Inventories, Raw Materials & Components depends on the Medical Distribution industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Guangzhou Baiyunshan Pharmaceutical Holdings Co and its competitors. Guangzhou Baiyunshan Pharmaceutical Holdings Co's current Inventories, Raw Materials & Components is HK$0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co (HKSE:00874) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$22.26, compared to a current price of HK$15.13 — trading 32% below its estimated fair value. The current Inventories, Raw Materials & Components is HK$0 Mil. Guangzhou Baiyunshan Pharmaceutical Holdings Co's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Guangzhou Baiyunshan Pharmaceutical Holdings Co (HKSE:00874), the current Inventories, Raw Materials & Components is HK$0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Guangzhou Baiyunshan Pharmaceutical Holdings Co (HKSE:00874) Overvalued in 2026?
Based on GuruFocus' analysis, Guangzhou Baiyunshan Pharmaceutical Holdings Co stock appears to be undervalued.
The current stock price of HK$15.13 is trading 32% below its estimated GF Value™ of HK$22.26.
GuruFocus considers Guangzhou Baiyunshan Pharmaceutical Holdings Co to be Significantly Undervalued.
Key valuation signals for HKSE:00874:
Inventories, Raw Materials & Components: HK$0 Mil
GF Value™: HK$22.26 vs. price of HK$15.13 (32% below fair value)
No single metric tells the full story. See the HKSE:00874 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
90GF Score
Get the complete analysis for HKSE:00874
Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00874 has been successfully added to your 
